GC Biopharma, Hanmi Pharm strike $475m Fabry disease drug deal with BioMarin

GC Biopharma and Hanmi Pharmaceutical announced on Friday that they have signed an exclusive licensing-out agreement with US biotech company BioMarin Pharmaceutical for their jointly developed experimental treatment for Fabry disease in a deal worth up to $475 million. Under the agreement, BioMarin will oversee the …

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.